FibroGen, Inc (FGEN) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Kyntra Bio, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.378 As a reminder, today's program is being recorded. 00:00:04.378 -- 00:00:10.006 And now I'd like to introduce your host for today's program, Gaia Shamus from LifeSci 00:00:10.006 -- 00:00:12.610 Advisors. Please go ahead. 00:00:12.610 -- 00:00:15.314 Thank you, Jonathan. Good afternoon, everyone. 00:00:15.314 -- 00:00:20.882 Thank you for joining us today to discuss FibroGen's second quarter 2025 financial 00:00:20.882 -- 00:00:25.229 and business results. I'm Gaia Shamus with LifeSci Advisors. 00:00:25.229 -- 00:00:30.896 Joining me on today's call are Fain Weddy, Chief Executive Officer, David DiLuccia, 00:00:30.896 -- 00:00:36.244 Chief Financial Officer, and Carol Gedham, Product Team Lead for FG3246, 00:00:36.244 -- 00:00:38.244 FG3180, 00:00:39.329 -- 00:00:41.111 and Roxadustat. 00:00:41.111 -- 00:00:44.757 Following the prepared remarks, we will open the call to your questions. 00:00:44.757 -- 00:00:48.963 I would like to remind you that remarks made on today's call include forward-looking 00:00:48.963 -- 00:00:54.592 statements about FibroGen. Such statements may include, but are not limited to, 00:00:54.592 -- 00:01:00.319 collaboration with AstraZeneca and Astellas, financial guidance, the initiation, 00:01:00.319 -- 00:01:06.004 enrollment, design, conduct, and results of clinical trials, regulatory strategies 00:01:06.004 -- 00:01:11.449 and potential regulatory results, research and development activities, commercial results 00:01:11.449 -- 00:01:16.494 and results of operations, risks related to our business, and certain other business 00:01:16.494 -- 00:01:17.915 matters. 00:01:17.915 -- 00:01:23.000 Each forward-looking statement is subject to risks and uncertainties that could cause 00:01:23.000 -- 00:01:28.287 act...